Published in PLoS One on May 02, 2012
Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell (2014) 1.90
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. Am J Pathol (2013) 1.14
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev (2013) 1.05
Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS One (2013) 0.95
Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. J Am Soc Nephrol (2014) 0.92
Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci (2013) 0.92
Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. Neurobiol Dis (2014) 0.89
Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis (2014) 0.86
The role of VEGF 165b in pathophysiology. Cell Adh Migr (2012) 0.86
Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther (2014) 0.83
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis Tissue Repair (2014) 0.79
Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis? J Endocrinol (2015) 0.77
Autocrine VEGF Isoforms Differentially Regulate Endothelial Cell Behavior. Front Cell Dev Biol (2016) 0.76
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther (2016) 0.75
RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFAxxxb isoforms. Sci Rep (2017) 0.75
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 14.39
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res (1997) 6.24
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 5.15
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 3.19
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 3.03
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem (1996) 2.58
Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn (2001) 2.53
The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat (1995) 2.39
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci (2008) 2.09
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia (2005) 2.09
Neuropilins in physiological and pathological angiogenesis. J Pathol (2007) 2.03
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci (2006) 1.92
The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer (2008) 1.85
Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer (2007) 1.75
VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis (2006) 1.71
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem (2009) 1.68
Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer (1998) 1.58
Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem (1997) 1.54
Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell (2010) 1.49
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res (2008) 1.39
Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer (1999) 1.37
Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett (2006) 1.35
Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J (2007) 1.34
Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol (2007) 1.30
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer (2008) 1.30
The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol (2008) 1.24
Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol Renal Physiol (2003) 1.24
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res (2008) 1.22
VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci (2010) 1.20
Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol (2009) 1.17
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer (1999) 1.16
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun (2002) 1.10
VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer (2009) 1.07
The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans (2009) 1.07
5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. Biomed Pharmacother (2007) 0.99
Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma. Mol Vis (2008) 0.98
Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell (2010) 0.95
Reverse transcription-polymerase chain reaction products of alternatively spliced mRNAs form DNA heteroduplexes and heteroduplex complexes. J Biol Chem (1999) 0.94
VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A. Mol Cancer (2010) 0.94
Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol (2009) 0.93
VEGF isoforms and mutations in human colorectal cancer. Int J Cancer (2002) 0.91
Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy. Exp Eye Res (2011) 0.90
Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol (2007) 0.79
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 5.15
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
Disrupting tumour blood vessels. Nat Rev Cancer (2005) 4.35
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol (2009) 2.80
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J (2002) 2.05
Delta-like 4 is indispensable in thymic environment specific for T cell development. J Exp Med (2008) 2.02
The role of vascular endothelial growth factor in ocular health and disease. Retina (2005) 1.81
Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol (2007) 1.76
"Never mind the logic, give me the numbers": former Australian health ministers' perspectives on the social determinants of health. Soc Sci Med (2013) 1.69
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest (2011) 1.66
Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev (2004) 1.65
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A (2005) 1.48
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res (2002) 1.47
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol (2002) 1.45
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci (2007) 1.38
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol (2009) 1.25
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res (2008) 1.22
A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome. PLoS One (2013) 1.22
Sequential SNARE disassembly and GATE-16-GOS-28 complex assembly mediated by distinct NSF activities drives Golgi membrane fusion. J Cell Biol (2002) 1.20
An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci U S A (2006) 1.20
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed (2002) 1.16
From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs (2005) 1.12
VEGF function in vascular pathogenesis. Exp Cell Res (2005) 1.10
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem (2007) 1.09
The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol (2002) 1.08
VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol (2013) 1.07
Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets (2007) 1.01
Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circ Res (2005) 1.00
Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther (2002) 0.99
RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis (2007) 0.95
The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study. Biochem Soc Trans (2009) 0.93
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer (2002) 0.92
The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood (2012) 0.91
Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Microcirculation (2008) 0.91
Forkhead box N4 (Foxn4) activates Dll4-Notch signaling to suppress photoreceptor cell fates of early retinal progenitors. Proc Natl Acad Sci U S A (2012) 0.91
Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc Natl Acad Sci U S A (2010) 0.90
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci (2008) 0.90
Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci (2007) 0.88
Delivery of anti-angiogenic molecular therapies for retinal disease. Drug Discov Today (2010) 0.87
Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Invest Ophthalmol Vis Sci (2013) 0.87
Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res (2002) 0.87
Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer (2006) 0.86
Why behavioural health promotion endures despite its failure to reduce health inequities. Sociol Health Illn (2014) 0.86
Application of intravital microscopy in studies of tumor microcirculation. J Biomed Opt (2010) 0.86
Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. J Cell Biochem (2002) 0.84
Alpha1,3-galactosyltransferase knockout does not alter the properties of porcine extracellular matrix bioscaffolds. Acta Biomater (2011) 0.84
Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability. Int J Radiat Oncol Biol Phys (2007) 0.83
Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization. Mol Vis (2006) 0.81
Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology. Acta Biochim Pol (2011) 0.81
CAIMAN: an online algorithm repository for Cancer Image Analysis. Comput Methods Programs Biomed (2010) 0.81
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate. Int J Cancer (2011) 0.81
Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol (2007) 0.81
Effects of tin-protoporphyrin IX on blood flow in a rat tumor model. Exp Biol Med (Maywood) (2003) 0.80
Recombinant " IMS TAG" proteins--a new method for validating bottom-up matrix-assisted laser desorption/ionisation ion mobility separation mass spectrometry imaging. Rapid Commun Mass Spectrom (2013) 0.80
Are the national preventive health initiatives likely to reduce health inequities? Aust J Prim Health (2011) 0.79
Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int J Radiat Oncol Biol Phys (2002) 0.79
Online chromatic and scale-space microvessel-tracing analysis for transmitted light optical images. Microvasc Res (2012) 0.79
Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. J Med Chem (2016) 0.78
Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Med Eng Phys (2010) 0.77
The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res (2003) 0.77
Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. Int J Cancer (2013) 0.77
Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model. Cancer Gene Ther (2004) 0.77
MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent. Proteomics (2014) 0.76
Targeting cancer with gene therapy using hypoxia as a stimulus. Methods Mol Med (2004) 0.76
Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution. BMC Cancer (2004) 0.75
Generation of a novel mouse model for the inducible depletion of macrophages in vivo. Genesis (2012) 0.75
Dear health minister: tend the garden but make sure you fence the crocodiles. J Epidemiol Community Health (2014) 0.75
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med (2017) 0.75
Detection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging. Eur J Mass Spectrom (Chichester, Eng) (2013) 0.75